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Résumé 
Contexte. - Décrire les pratiques de dépistage de l’hépatite B au cours du temps chez les 
patients infectés par le VIH en Afrique de l'Ouest. 
Méthodes. - Une enquête a été menée dans les centres urbains de prise en charge du VIH 
en Côte d'Ivoire (3 sites), Bénin, Burkina Faso, Sénégal et Togo (1 site chacun). Parmi les 
patients ayant été instaurés sous traitement antirétroviral entre 2010 et 2012, 100 ont été tirés 
au sort chaque année dans chaque clinique. Les informations ont été recueillies à partir des 
dossiers médicaux. Les facteurs associés au dépistage de l’hépatite B ont été recherchés par 
régression logistique. 
Résultats. - Au total, 2 097 patients ont été inclus (âge médian de 37 ans, 65,4 % de femmes). 
Le dépistage de l’hépatite B a été réalisé chez 313 (14,9 %) patients, avec une augmentation 
au cours du temps (de 10,6 % en 2010 à 18,9 % en 2012, P<0,001), et une variation entre les 
centres. Un âge > 45 ans [rapport de cotes ajusté : 1,34 (1,01-1,77)] et une activité génératrice 
de revenus [rapport de cotes ajusté : 1,82 (1,09-3,03)] étaient associés au dépistage de 
l’hépatite B. La prévalence de l’hépatite B chronique (AgHBs+) était de 19,8 % (15,5-24,7) et 
82,3 % des co-infectés étaient traités par ténofovir.  
Conclusion. - Entre 2010 et 2012, le dépistage de l’hépatite B chez les patients infectés par 
le VIH était faible. La disponibilité croissante des tests rapides de recherche de l’AgHBs et du 
ténofovir devrait améliorer ce dépistage. 
 
 
Abstract 
Background. - We aimed to describe changes in hepatitis B screening practices over a 3-year 
period among HIV-infected patients in West Africa.  
Methods. - A medical chart review was conducted in urban HIV treatment centers in Ivory 
Coast (3 sites), Benin, Burkina Faso, Senegal, and Togo (1 site each). Among patients who 
started antiretroviral treatment between 2010 and 2012, 100 per year were randomly selected 
from each clinic. Demographic, clinical, and laboratory data was collected using a standardized 
questionnaire. We assessed changes in the proportion of patients screened over time and 
identified predictors of screening in a multivariable logistic regression.  
Results. - A total of 2,097 patients were included (median age: 37 years, 65.4% of women). 
Overall, 313 (14.9%) patients had been screened for hepatitis B, with an increase from 10.6% 
in 2010 to 18.9% in 2012 (P<0.001) and substantial differences across countries. In 
multivariable analysis, being aged over 45 years [adjusted odds ratio: 1.34 (1.01-1.77)] and 
having an income-generating activity [adjusted odds ratio: 1.82 (1.09-3.03)] were associated 
with screening for hepatitis B infection. Overall, 62 HIV-infected patients (19.8%, 95% 
confidence interval: 15.5-24.7) were HBsAg-positive and 82.3% of them received a tenofovir-
containing drug regimen.  
Conclusion. - Hepatitis B screening among HIV-infected patients was low between 2010 and 
2012. The increasing availability of HBsAg rapid tests and tenofovir in first-line antiretroviral 
regimen should improve hepatitis B screening rates. 
 
 
 
  
Introduction 
At the end of 2014, the World Health Organization (WHO) estimated the number of HIV-
infected people at 36.9 million [34.3-41.4] and at 2.0 million [1.9-2.2] the annual number of new 
infections worldwide [1]. Sub-Saharan Africa remained the most affected region, with 25.8 
million [24.0–28.7] HIV-infected people and an estimated 70% of new infections [1]. Sub-
Saharan Africa is also one of the most affected regions for hepatitis B virus (HBV), with more 
than 8% of the general population presenting with chronic HBV infection [2-4]. HBV infection 
is one of the main causes of cirrhosis and hepatocellular carcinoma (HCC) [5-8]. However, 
most patients infected with HBV are unaware of their status as routine screening for HBV in 
the general population is lacking [4]. 
As both infections share the same contamination routes (blood or sexual routes, or mother-to-
child transmission), HIV-HBV co-infection is frequent, with 8-25% of HIV-infected patients who 
also present with chronic HBV infection in Sub-Saharan Africa [9-15]. HIV-HBV co-infected 
patients are at higher risk of death, poor immune reconstitution, and hepatotoxicity on 
antiretroviral therapy (ART) than patients only presenting with HIV infection [16-20].  
WHO has been recommending since 2010 the systematic HBV screening in HIV-infected 
patients before ART initiation. Most national HIV/AIDS programs have now integrated this 
recommendation. HBV status ascertainment in HIV-infected patients is very important as it 
helps optimize the management of HIV-HBV co-infected patients with the initiation of a first-
line ART combining at least two molecules active against both HIV and HBV, namely tenofovir 
(TDF) and lamivudine (3TC) or emtricitabine (FTC) [21]. HBV status ascertainment in HIV-
infected patients also contributes to guiding the second-line treatment choice in case of failure 
of the initial ART. 
The prevalence of HBV among HIV-infected patients in Sub-Saharan Africa has already been 
measured, but the implementation of guidelines on systematic HBV screening in HIV-infected 
patients at initial management or ART initiation has rarely been documented. A recent study 
conducted in Zambia in 15 healthcare facilities of Lusaka revealed a sharp increase in 
systematic HBV screening in HIV-infected patients between 2008 (1.0% of HIV-infected 
patients) and 2012 (46.8%) [22], with substantial differences in terms of timing of screening 
implementation by facility. To our knowledge, in West Africa, detailed data on HBV screening 
practices in HIV-infected patients and on changes in these practices over time is still lacking.  
We aimed to measure the proportion of treated HIV-infected patients screened for HBV, to 
describe changes in HBV screening practices over time, and to assess factors associated with 
HBV screening in a sample of HIV clinics in West Africa. 
 
Methods 
Type of study 
We performed a retrospective, multicenter study in several HIV clinics of West Africa that are 
part of the IeDEA Collaboration (International epidemiological DataBase to Evaluate AIDS) 
[23].  
Study framework 
We selected five French-speaking countries for the study (Benin, Burkina Faso, Ivory Coast, 
Senegal, and Togo). We selected a university hospital reference center for HIV management 
in each country. Two urban health clinics with several years of experience in HIV-infected 
patient management were also selected in Abidjan, Ivory Coast. 
Study sample and data collection 
Each year, a total of 100 individuals were randomly selected in each clinic (i.e., maximum of 
300 patients per clinic) among adult HIV-infected patients (≥18 years) initiated on ART in the 
participating clinics between January 1, 2010 and December 31, 2012. When the number of 
patients initiated on ART was <100 for a given year, all patients were selected. Using a 
standardized questionnaire on HBV screening and management and patients’ files, we 
collected socio-demographic, clinical, and biological data as well as data related to HBV 
screening practices.  
Ethical consideration 
This study was approved by the Ethical Committee of each of the five participating countries. 
Patient data was computerized using a unique code and no personal identifier was entered 
into the database. All patients were informed that data collected during routine visits would be 
collected and used for research purposes. 
 
Statistical analyses 
Quantitative variables were expressed as median and interquartile range (IQR). Qualitative 
variables were expressed as numbers and percentages. The univariate comparison of 
medians was performed using Kruskal-Wallis test, and that of frequencies using Chi-square 
test or Fisher’s exact test depending on characteristics. The proportion of patients screened 
for HBV and the prevalence of HBV were calculated with their corresponding 95% confidence 
interval (95% CI). We used a univariable and then a multivariable logistic regression model to 
look for factors associated with HBV screening. Data was processed using the STATA software 
(StataTM 9.0 College Station, Texas, USA). 
 
Results 
Study sample 
Overall, 2,097 patients were included in the study: 300 in each of the seven facilities, except 
for the clinic in Dakar, Senegal (n=297). Median age of patients at ART initiation was 37 years 
[IQR: 32-45] and median CD4 counts and alanine aminotransferase (ALAT) levels were 206 
cells/mm3 [IQR: 108-310] and 21 IU/l [IQR: 16-29], respectively. Approximately two-thirds of 
patients (65.4%) were women and 97.0% were only infected with HIV-1. First-line ART most 
often combined two nucleoside reverse transcriptase inhibitors (NRTIs) and one non-
nucleoside reverse transcriptase inhibitor (NNRTI) (91.9%); 595 (28.3%) patients were initiated 
on TDF-based therapy: with a minimum of 13.0% in Benin and a maximum of 41.1% in 
Senegal. 
Table I summarizes patients’ characteristics at ART initiation. 
Hepatitis B screening 
HBV screening was performed in 313 patients (14.9%, 95% CI: 13.4-16.5), with an increase in 
the proportion of screening over time: 10.6% of HIV-infected patients initiated on treatment in 
2010, 15.3% in 2011, and 18.9% in 2012 (P<0.001) (Figure 1). This proportion of HBV 
screening also differed by country, irrespective of the year (4.1% in Ivory Coast, 10.0% in Togo, 
11.7% in Benin, 25.3% in Burkina Faso, and 45.5% in Senegal; P<0.001) (Figure 1). Except 
for Senegal and Burkina Faso where the proportion of patients screened for HBV substantially 
increased over the years, this proportion remained below 20% in the other countries (Figure 
1). Most tested patients (86.3%) were screened before ART initiation, and the HBsAg test was 
the only one performed for 82.4% of patients. Patients with a positive HBsAg test were never 
offered an HBV viral load measurement. 
Reasons for screening 
Among the 313 tested patients, HBV screening was systematically performed in 201 patients 
(64.2%); it was performed as part of a research protocol for 29 patients (9.3%); and because 
of an HBV suspicion (high aminotransferase level defined by ALAT >40 IU/l) or by jaundice) in 
44 patients (14.0%). Reasons for HBV screening was not mentioned in the patient’s file in 
12.5% of cases. Systematic HBV screening proportionally increased over the years (2.6% of 
all HIV-infected patients in 2010, 10.5% in 2011, and 15.7% in 2012, for all countries; P<0.001), 
while that same proportion remained stable or decreased over time for all the other reasons 
(Figure 2).  
Prevalence of HBsAg and risk factors 
Overall, 62 patients (19.8%; 95% CI [15.5-24.7]) had a positive HBsAg test. This prevalence 
varied by country (14.3% of tested patients in Benin, 18.5% in Senegal, 20.0% in Togo, 21.1% 
in Burkina Faso, and 27.0% in Ivory Coast; P<0.001), and by reason for screening (50.0% for 
high aminotransferase level, 18.7% for systematic screening, 17.2% for screening as part of a 
research protocol, and 17.6% for undocumented reason; P<0.001).  
Among patients with a positive HBsAg test, 51 (82.3%) had been prescribed an ART with TDF 
and 3TC (or FTC). The proportion of these patients increased over time (from 55.6% in 2010 
to 91.7% in 2012; P<0.001). Among patients with a negative HBsAg test or who were not 
screened for HBV, 29.2% received a TDF-based treatment. The proportion of these patients 
also increased over time: from 20.8% in 2010 to 39.0% in 2012. 
Factors associated with HBV screening 
Based on the multivariate analysis adjusted for sex, patients aged above 45 years were more 
likely to be screened for HBV (adjusted odds ratio [aOR]=1.34; 95% CI [1.01-1.77]) than 
patients aged 45 years or below. Patients with an income-generating activity were also more 
likely to be screened for HBV (aOR=1.82; 95% CI [1.09-3.03]) than patients without any 
income-generating activity. Patients for whom such information was lacking were not more 
often screened for HBV (Table II). 
 
Discussion 
This study is one of the first conducted in West Africa to report the proportion of HIV-infected 
patients screened for HBV and the changes in HBV screening practices over time. Among 
more than 2,000 patients treated for HIV between 2010 and 2012 in seven urban clinics of 
West Africa, only 313 (14.9%) were screened for HBV, even though screening practices slightly 
increased over the three years. We observed substantial differences between countries (a 
minimum of 4% in Ivory Coast and a maximum of 50% of patients in Senegal). Twenty per cent 
of patients who had been screened for HBV presented with a chronic HBV infection defined by 
a positive HBsAg test; 80% of these patients had been prescribed TDF-based ART. Patients 
aged above 45 years and patients with an income-generating activity were more likely to be 
screened for HBV than other patients. 
As this study was retrospective, we could not: 1) document the prescription of an HBV 
screening test by physicians; this would have helped assess the proportion of HBV tests 
actually performed among those prescribed; 2) precisely collect important data to characterize 
the profile of non-screened patients, especially data related to level of education, occupation, 
or level of income; 3) collect and precisely describe all reasons for screening (12.5% of missing 
data for this item). 
Findings from our study revealed that despite a recent increase, HBV screening in treated HIV-
infected patients is still uncommon in West Africa as only 19% of patients were tested in 2012. 
Two factors could explain this low proportion: 1) the delay, at country level, in implementing 
international and national guidelines on systematic screening for HBV in HIV-infected patients 
before ART initiation. Most study countries started implementing those guidelines in 2010 
following international guidelines issuance, and a period of adjustment was probably needed 
for them to be widely distributed and for training healthcare professionals, as highlighted by 
the progressive increase in the proportion of patients screened for HBV over the years. This 
period of adjustment varied by country and probably resulted in the substantial differences in 
the results observed in the various study clinics. Conversely, the conduct of HBV prevalence 
studies in at least one participating clinic may have interfered with routine practices [10]; 2) as 
rapid diagnostic tests were not or were poorly available during the study period, HBV screening 
was mainly based on ELISA tests which relatively high cost was at the expense of patients. 
Only well off patients, including those with an income-generating activity, could thus access 
HBV screening as shown in our study. This subgroup of patients was indeed twice more likely 
to be screened for HBV than other HIV-infected patients. Rapid HBsAg detection tests have 
been associated with very good performances in industrialized countries [24], East and West 
Africa [25-28]. They are now available and most HIV-infected patients should have access to 
HBV screening.  
We did not observe any differences in the proportion of HBV screening by CD4 count levels. 
Although international and national guidelines recommend the systematic screening of all HIV-
infected patients regardless of their CD4 count, particular attention should be paid to patients 
with low CD4 count (<200 cells/mm3) or even very low CD4 count (<50 cells/mm3). The 
absence of HBV screening and adequate management in these patients could be associated 
with a severe risk of hepatic decompensation due to an immune reconstitution inflammatory 
syndrome at ART initiation [29]. 
The prevalence of HBV infection (positive HBsAg test) observed in our study was 19.8%; this 
figure is higher than that usually reported in HIV-infected patients in West Africa (8%-15%) [9-
11, 13, 30-32]. This difference could be partly explained by our conducting the study in highly 
specialized university hospitals that manage patients presenting with advanced HIV infection. 
Also, our study did not focus on serological monitoring but on collecting data related to HBV 
screening practices which was far from being systematically performed despite 
recommendations. A significant proportion of tested patients (14.0%) was thus screened for 
HBV because of an HBV infection suspicion. Among tested patients co-infected with HIV and 
HBV, 82.3% received a TDF-based ART. This prescription increased over the years and 
reached 91.7% in 2012. This increase highlights the progressive and marked improvement of 
HBV management practices. 
More than five years after the publication of the first guidelines on HBV screening in HIV-
infected patients, and considering the growing availability of rapid HBsAg detection tests in 
West Africa, changes in HBV screening in HIV-infected patients should keep on being regularly 
assessed as these patients should be rapidly initiated on ART [33]. 
Despite the slight increase in the proportion of HIV-infected patients screened for HBV between 
2010 and 2012, our findings showed that HBV screening is still uncommon in West Africa and 
that it still varies widely by country. Involvement of health authorities and healthcare 
professionals, use of rapid diagnostic tests for HBV - now widely available - and use of TDF 
as the backbone molecule of first-line ART should help improve HBV screening and 
management of patients co-infected with HIV and HBV. We plan to perform the same study 
over the 2015-2017 period to assess practice compliance with international guidelines on 
screening and treatment. 
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Tableau I. Caractéristiques des patients vivant avec le VIH à la mise sous traitement antirétroviral dans cinq pays d’Afrique de l’Ouest, 2010-
2012 (N = 2 097). Collaboration IeDEA West Africa. 
Table I. Characteristics of HIV-infected patients at antiretroviral therapy initiation in five West African countries (N=2,097). IeDEA West Africa 
Collaboration. 
Variables Total Benin Burkina Faso Ivory Coast Senegal  Togo 
 N=2,097 N=300 N=300 N=900 N=297 N=300 
Age 
(years) 
      
Median [IQR] 37 [32-45] 35 [30-42] 35 [30-42] 38 [33-45] 41 [35-49] 35 [30-43] 
n (%) ≤45 1,626 (77.5) 249 (83.0) 253 (84.3) 684 (76.0) 195 (65.7) 245 (81.7) 
n (%) >45 471 (22.5) 51 (17.0) 47 (15.7) 216 (24.0) 102 (34.3) 55 (18.3) 
Sex       
Male 726 (34.6) 102 (34.0) 84 (28.0) 319 (35.4) 118 (39.7) 103 (34.3) 
Female 1,371 (65.4) 198 (66.0) 216 (72.0) 581 (64.6) 179 (60.3) 197 (65.7) 
Type of HIV infection (%)       
HIV-1 2,035 (97.0) 298 (99.3) 289 (96.3) 858 (95.3) 290 (97.6) 300 (100.0) 
HIV-2 or HIV-1&2 62 (3.0) 2 (0.7) 11 (3.7) 42 (4.7) 7 (2.4) 0 (0.0) 
Occupation       
Without any income-generating 
activity 
164 (7.8) 26 (8.7) 9 (3.0) 67 (7.4) 62 (20.9) 0 (0.0) 
With an income-generating activity 1,304 (62.2) 257 (85.7) 290 (96.7) 521 (57.9) 222 (74.7) 14 (4.7) 
Not mentioned 629 (30.0) 17 (5.7) 1 (0.3) 312 (34.7) 13 (4.4) 286 (95.3) 
CD4 cells/mm3       
Median [IQR] 206 [108-310] 198 [81-316] 205 [102-321] 217 [102-326] 217 [155-280] 170 [96-249] 
≤200 1,017 (48.5) 159 (53.0) 145 (48.3) 412 (45.8) 113 (38.1) 188 (62.7) 
>200 1,080 (51.5) 141 (47.0) 155 (51.7) 488 (54.2) 184 (61.9) 112 (37.3) 
ALAT level (IU/L)       
Median [IQR] 21 [16-29] 22 [18-35] 20 [12-28] 20 [14-30] 21 [21-22] 25 [21-33] 
≤40 1,824 (87.0) 248 (82.7) 270 (90.0) 766 (85.1) 287 (96.6) 254 (84.7) 
>40 272 (13.0) 52 (17.3) 30 (10.0) 134 (14.9) 10 (3.4) 46 (15.3) 
Antiretroviral therapy       
2 NRTIs + 1 NNRTI 1,926 (91.9) 298 (99.3) 269 (89.7) 786 (87.3) 286 (96.3) 287 (95.7) 
3 NRTIs 24 (1.1) 0 (0.0) 0 (0.0) 22 (25.4) 2 (0.7) 0 (0.0) 
2 NRTIs + 1 PI 147 (7.0) 2 (0.7) 31 (10.3) 92 (10.2) 9 (3.0) 13 (4.3) 
TDF-based regimen       
Yes 595 (28.4) 39 (13.0) 87 (29.0) 303 (33.7) 122 (41.1) 44 (14.7) 
No 1,502 (71.6) 261 (87.0) 213 (71.0) 597 (66.3) 175 (58.9) 256 (85.3) 
IQR: interquartile range 
ALAT: alanine aminotransferase 
NRTI: nucleoside reverse transcriptase inhibitor 
NNRTI: non-nucleoside reverse transcriptase inhibitor 
PI: protease inhibitor  
TDF: tenofovir 
  
Tableau II. Facteurs associés au dépistage de l’hépatite B chez les patients infectés par le VIH dans cinq pays d’Afrique de l’Ouest (N = 2 097). 
Collaboration IeDEA West Africa. 
Table II. Factors associated with hepatitis B screening among HIV-infected patients in five West African countries (N=2,097)  
     Univariate analysis  Multivariate analysis 
  N n (%)  OR 95% CI  p  aOR 95% CI  p 
Age 
 
           
≤45  1,626 227 (14.0)  Ref. - -  Ref. - - 
>45    471  86 (18.3)  1.38 1.04-1.81 0.022  1.34 1.01-1.77 0.04 
Sex            
Female  1,371 190 (13.9)  Ref. - -  Ref. - - 
Male    726 123 (16.9)  1.27 0.99-1.62 0.06  1.22 0.95-1.57 0.13 
Type of HIV            
HIV-1  2,035 305 (15.0)  Ref. - -     
HIV-2 or HIV-1&2      62    8 (12.9)  0.84 0.40-1.78 0.65     
Occupation            
Without any income-
generating activity 
  164   18 (11.0)  Ref. - -  Ref. - - 
With an income-
generating activity 
  984 236 (18.1)  1.79 1.08-2.98 0.03  1.82 1.09-3.03 0.02 
Not mentioned   629 59 (9.4)  0.84 0.48-1.47 0.54  0.84 0.48-1.47 0.55 
CD4 count (/mm3)            
>200  1,080 162 (15.0)  Ref. - -     
≤200  1,017 151 (14.9)  0.99 0.78-1.26 0.92     
ALAT level (IU/L)            
≤40  1,825 268 (14.7)  Ref. - -     
>40  272 45 (16.5)  1.15 0.81-1.63 0.42     
N: Number in each group; n (%): number and percentage of patients screened for HBV 
ALAT: alanine aminotransferase 
OR: odds ratio   
aOR: adjusted odds ratio  
95% CI: 95% confidence interval 
Ref.: reference class 
Figure 1. Évolution de la proportion de dépistage de l’hépatite B chez les personnes vivant avec le VIH pris en charge 
dans les cinq pays d’Afrique de l’Ouest de 2010 à 2012. Collaboration IeDEA West Africa.   
 
Figure 1. Evolution of the proportion of hepatitis B screening among HIV-infected patients in five West African countries 
from 2010 to 2012. IeDEA West Africa Collaboration 
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 Figure 2. Évolution des motifs de dépistage de l’hépatite B chez les personnes vivant avec le VIH pris en charge dans cinq 
pays d’Afrique de l’Ouest de 2010 à 2012. Collaboration IeDEA West Africa. 
 
Figure 2. Evolution of reasons for hepatitis B screening among HIV-infected patients in five West African countries from 2010 
to 2012. IeDEA West Africa Collaboration 
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